News
Topline data were announced from two phase 3 studies evaluating MR-107A-02 for the treatment of moderate to severe acute pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback